MFG
RLAY icon

Merit Financial Group’s Relay Therapeutics RLAY Stock Holding History

Merit Financial Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Sell
20,613
-387
-2% -$5.62K ﹤0.01% 1659
2026
Q1 		$209K Buy
21,000
+515
+3% +$4.61K ﹤0.01% 1900
2025
Q4 		$173K Sell
20,485
-29
-0.1% -$207 ﹤0.01% 1841
2025
Q3 		$107K Buy
20,514
+22
+0.1% +$84 ﹤0.01% 1731
2025
Q2 		$70.9K Buy
+20,492
New +$61K ﹤0.01% 1653

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Merit Financial Group's RLAY Position: Q2 2026 in Review

Merit Financial Group reduced its Relay Therapeutics (RLAY) stake by 1.8% in Q2 2026, selling an estimated $5.62K and leaving 20,613 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Merit Financial Group first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Merit Financial Group held 20,613 shares of Relay Therapeutics worth $386K as of Q2 2026.
  • Merit Financial Group sold 387 Relay Therapeutics shares in Q2 2026, an estimated $5.62K.
  • Relay Therapeutics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1659 holding.
  • Merit Financial Group first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.